Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3930713 | 0.98 | L3MBTL3 (0.33) | L3MBTL3 | |
| SCHEMBL9089960 | 0.72 | — | — | |
| SCHEMBL2689541 | 0.70 | — | — | |
| SCHEMBL31054194 | 0.70 | — | — | |
| SCHEMBL4124685 | 0.70 | — | — | |
| SCHEMBL7762129 | 0.67 | EPHX2 (0.30) | — | |
| SCHEMBL4123586 | 0.67 | — | — | |
| SCHEMBL4130201 | 0.65 | — | — | |
| SCHEMBL4135728 | 0.64 | ALDH1A1 (0.31) | — | |
| SCHEMBL4118534 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752640-B2 | Compounds active towards bromodomains | NUEVOLUTION A/S (DK) | 2020-08-25 | — | — | US | disclosed |
| US-20170349607-A1 | COMPOUNDS ACTIVE TOWARDS BROMODOMAINS | NUEVOLUTION A/S (DK) | 2017-12-07 | — | — | US | disclosed |
| US-7595314-B2 | Benzoyl-piperazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-20090192136-A1 | BENZOYL-PIPERAZINE DERIVATIVES | ALBERATI-GIANI DANIELA | 2009-07-30 | — | — | US | disclosed |
| US-7427612-B2 | Benzoyl-piperazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-20050070539-A1 | Benzoyl-piperazine derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070539-A1 | Benzoyl-piperazine derivatives | OPRL1, ACHE, PNMT | L3MBTL3 2134/4885 |
| US-20090192136-A1 | BENZOYL-PIPERAZINE DERIVATIVES | OPRL1, ACHE, PNMT | L3MBTL3 2134/4885 |
| US-20170349607-A1 | COMPOUNDS ACTIVE TOWARDS BROMODOMAINS | BRD4, BRD3, BRDT | L3MBTL3 2713/4885 |
| US-10752640-B2 | Compounds active towards bromodomains | BRD4, BRD3, BRDT | L3MBTL3 2713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.